The world’s largest biotech firm, based in Thousand Oaks, Calif., reported net income was $788M, or $1.01 a share, for the quarter ended Dec. 31. That was decreased from $934M, or $1.08 a share, a year before.
While the excluding one-time items, net income would have been $1.40 a share. That is 4 cents lower than analysts anticipated, on average, according to research provider FactSet.
Shares of Amgen, Inc. (NASDAQ:AMGN) traded at $83.07 by plunging -0.26% with price volatility of 1.80% for a week and 1.63% for a month plus price volatility’s Average True Range for 14 days was 1.41 and its beta stands at 1.63 times.
Stocks after opening at $83.06 hit high price of $84.49 and on last session stock held volume of 7.67 million shares which was unexpectedly higher than its average volume of 4.75 million shares.
Short-term as well long term investors always focus on the liquidity of the stocks so for that concern, liquidity measure in recent quarter results of the company was recorded 3.90 as current ratio and on the opponent side the debt to equity ratio was 1.33 and long-term debt to equity ratio also remained 1.21. The Company had total cash at hand $25.37 billion and a book value per share as $25.91 in the most recent quarter.
While investors who viewing AMGN against other stocks with the reference of profit margin that are Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) having profit margin -316.94%, Dendreon Corporation (NASDAQ:DNDN) with -71.65% profit margin, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) having -378.08% profit margin and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) having profit margin of 21.32%.
Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Entire Disclaimer Here
© 2013
0 comments